Ramaswamy Govindan
#130,462
Most Influential Person Now
Ramaswamy Govindan's AcademicInfluence.com Rankings
Ramaswamy Govindancomputer-science Degrees
Computer Science
#5712
World Rank
#6031
Historical Rank
Data Mining
#117
World Rank
#117
Historical Rank
Machine Learning
#1616
World Rank
#1638
Historical Rank
Database
#2851
World Rank
#2976
Historical Rank
Ramaswamy Govindanbiology Degrees
Biology
#8577
World Rank
#11675
Historical Rank
Bioinformatics
#94
World Rank
#96
Historical Rank
Computational Biology
#164
World Rank
#165
Historical Rank
Download Badge
Computer Science Biology
Ramaswamy Govindan's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science Stanford University
Similar Degrees You Can Earn
Why Is Ramaswamy Govindan Influential?
(Suggest an Edit or Addition)Ramaswamy Govindan's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Comprehensive molecular profiling of lung adenocarcinoma (2014) (4095)
- Comprehensive genomic characterization of squamous cell lung cancers (2012) (2998)
- Oncogenic Signaling Pathways in The Cancer Genome Atlas (2018) (1646)
- Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. (2006) (1585)
- Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) (1360)
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity (2019) (1020)
- Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers (2012) (890)
- Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas (2016) (826)
- Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology (2017) (805)
- Sex and gender: modifiers of health, disease, and medicine (2020) (589)
- Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. (2016) (551)
- Pathogenic Germline Variants in 10,389 Adult Cancers (2018) (501)
- NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. (2019) (490)
- Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients (2018) (471)
- Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. (2013) (449)
- Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. (2008) (432)
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. (2020) (430)
- Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey (2007) (427)
- DGIdb - Mining the druggable genome (2013) (418)
- Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (411)
- NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. (2018) (411)
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation. (2021) (393)
- NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. (2016) (382)
- Patterns of somatic structural variation in human cancer genomes (2020) (377)
- Non-Small Cell Lung Cancer, Version 6.2015. (2015) (373)
- In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM (2003) (359)
- Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. (2017) (347)
- PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. (2013) (324)
- Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. (2008) (323)
- PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. (2016) (317)
- Non-small cell lung cancer, version 2.2013: Featured updates to the NCCN guidelines (2013) (313)
- A Gene Expression Signature Predicts Survival of Patients with Stage I Non-Small Cell Lung Cancer (2006) (311)
- Differential prognostic impact of comorbidity. (2004) (300)
- Non-small cell lung cancer. (2012) (277)
- Genomic alterations in lung adenocarcinoma. (2015) (276)
- Non-small cell lung cancer. Clinical practice guidelines in oncology. (2004) (269)
- Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. (2017) (258)
- Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B (2005) (254)
- The oligometastatic state—separating truth from wishful thinking (2014) (250)
- Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma (2020) (244)
- Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. (2004) (243)
- Lung cancer in never smokers: a review. (2007) (235)
- Non-small cell lung cancer, version 2.2013. (2013) (234)
- A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer (2020) (231)
- Clinical Implications of Genomic Discoveries in Lung Cancer. (2016) (230)
- Patterns and functional implications of rare germline variants across 12 cancer types (2015) (222)
- Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. (2011) (221)
- Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. (2009) (209)
- Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. (2012) (207)
- Clinical next‐generation sequencing in patients with non–small cell lung cancer (2015) (197)
- Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context (2018) (188)
- Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base. (2015) (187)
- Transcriptome sequencing reveals altered long intergenic non-coding RNAs in lung cancer (2014) (186)
- Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. (2006) (183)
- Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study (2021) (168)
- Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. (2018) (168)
- Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. (2011) (167)
- Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study (2019) (159)
- Distinctive Characteristics of Non-small Cell Lung Cancer (NSCLC) in the Young: A Surveillance, Epidemiology, and End Results (SEER) Analysis (2010) (155)
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) (2018) (154)
- Non-small cell lung cancer, version 1.2015. (2014) (154)
- Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. (2016) (153)
- Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. (2006) (150)
- Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. (2015) (144)
- Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors (2019) (144)
- A survey of Internet utilization among patients with cancer (2011) (143)
- MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. (2012) (143)
- A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing (2007) (143)
- Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117. (2010) (142)
- Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? (2016) (141)
- A Phase II Study of AT-101 (Gossypol) in Chemotherapy-Sensitive Recurrent Extensive-Stage Small Cell Lung Cancer (2011) (138)
- PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer (2014) (132)
- Smoking Relapse during the First Year after Treatment for Early-Stage Non–Small-Cell Lung Cancer (2006) (128)
- Molecular genetics of lung cancer in people who have never smoked. (2008) (124)
- SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. (2019) (124)
- Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. (2015) (123)
- Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors. (2019) (123)
- The epidemiology of bronchioloalveolar carcinoma over the past two decades: analysis of the SEER database. (2004) (120)
- Small cell lung cancer. (2011) (120)
- Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer (2012) (118)
- CHESS improves cancer caregivers' burden and mood: results of an eHealth RCT. (2014) (118)
- ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial. (2006) (115)
- Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb‐B2 (2005) (114)
- Non–small‐cell Lung Cancer With Brain Metastasis at Presentation (2018) (108)
- Non-small cell lung cancer. (2010) (103)
- EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. (2007) (99)
- Prognostic Value of Preoperative Positron Emission Tomography in Resected Stage I Non-small Cell Lung Cancer (2008) (96)
- Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer. (2007) (93)
- Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer (2018) (92)
- ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non–Small Cell Lung Cancer (2015) (90)
- Repeatability of 18F-FDG PET/CT in Advanced Non–Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials (2015) (88)
- An eHealth system supporting palliative care for patients with non–small cell lung cancer (2013) (87)
- PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. (2007) (86)
- A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117. (2010) (84)
- Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451 (2021) (83)
- Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts (2019) (81)
- A proteogenomic portrait of lung squamous cell carcinoma (2021) (77)
- Phase II Study of Cediranib (AZD 2171), an Inhibitor of the Vascular Endothelial Growth Factor Receptor, for Second-Line Therapy of Small Cell Lung Cancer (National Cancer Institute #7097) (2010) (76)
- NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. (2016) (76)
- Improving Survival for Stage IV Non-small Cell Lung Cancer: A Surveillance, Epidemiology, and End Results Survey from 1990 to 2005 (2009) (76)
- Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study. (2019) (76)
- Smoking urges and relapse among lung cancer patients: findings from a preliminary retrospective study. (2004) (75)
- SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC. (2014) (75)
- Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV (2009) (68)
- Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer (2017) (65)
- Use of MicroRNA Expression Levels to Predict Outcomes in Resected Stage I Non-small Cell Lung Cancer (2010) (64)
- Locally advanced non-small cell lung cancer: the past, present, and future. (2008) (64)
- Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response. (2003) (63)
- Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer (2018) (63)
- Presentation and Stage-Specific Outcomes of Lifelong Never-smokers with Non-small Cell Lung Cancer (NSCLC) (2007) (62)
- Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC (2016) (62)
- Hedgehog signaling pathway and lung cancer. (2007) (62)
- New approaches to small cell lung cancer therapy : from the laboratory to the clinic. (2020) (60)
- Targeting Angiogenesis with Multitargeted Tyrosine Kinase Inhibitors in the Treatment of Non-Small Cell Lung Cancer (2010) (60)
- Correlation of PD‐L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early‐Stage Squamous Cell Lung Carcinoma (2019) (60)
- JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC). (2019) (58)
- Risk of Recurrence of Resected Stage I Non-small Cell Lung Cancer in Elderly Patients as Compared with Younger Patients (2009) (58)
- Integrated analysis of genomic and transcriptomic data for the discovery of splice-associated variants in cancer (2018) (57)
- The Effect of FDG-PET on the Stage Distribution of Non-small Cell Lung Cancer (2008) (55)
- Thymomas and thymic carcinomas (2013) (54)
- Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01–24/USO-023 (2007) (54)
- Rovalpituzumab tesirine , a DLL 3-targeted antibody-drug conjugate , in recurrent small-cell lung cancer : a fi rst-inhuman , fi rst-in-class , open-label , phase 1 study (2016) (54)
- Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. (2017) (53)
- Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey from 1998 to 2003 (2012) (53)
- Routine positron emission tomography does not alter nodal staging in patients undergoing EUS-guided FNA for esophageal cancer. (2009) (52)
- A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC). (2004) (51)
- Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. (2013) (50)
- Malignant hematopoietic breast tumors. (1997) (50)
- Metastatic cancer involving bladder: a review. (2007) (50)
- ALCHEMIST: Bringing genomic discovery and targeted therapies to early‐stage lung cancer (2015) (48)
- Rapid induction of lung adenocarcinoma by fibroblast growth factor 9 signaling through FGF receptor 3. (2013) (48)
- A deep learning approach to automate refinement of somatic variant calling from cancer sequencing data (2018) (48)
- Biostatistics primer: what a clinician ought to know: hazard ratios. (2011) (48)
- Paclitaxel Plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer: A Safety, Feasibility, and Efficacy Study from the Hoosier Oncology Group (2010) (47)
- Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer (2017) (47)
- Review of Ongoing Clinical Trials in Non–Small-Cell Lung Cancer: A Status Report for 2012 from the ClinicalTrials.gov Web Site (2010) (47)
- Barriers to Enrollment in Non-small Cell Lung Cancer Therapeutic Clinical Trials (2011) (46)
- Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407. (2009) (44)
- Bortezomib ± docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): A phase 2 study (2005) (43)
- Tracheo-esophageal fistula with bevacizumab after mediastinal radiation. (2008) (42)
- Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. (2004) (41)
- Prognostic Value of Fluorodeoxyglucose Positron Emission Tomography in Non-small Cell Lung Cancer: A Review (2006) (41)
- A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC): Final results (2005) (40)
- Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin®, in resistant solid tumor malignancies (2009) (40)
- Lung cancer in 'Never-smokers': a unique entity. (2010) (39)
- cDNA hybrid capture improves transcriptome analysis on low-input and archived samples. (2014) (39)
- Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non–Small-Cell Lung Cancer (2013) (38)
- Identification of a novel tumor suppressor gene p34 on human chromosome 6q25.1. (2007) (38)
- Biostatistics primer: what a clinician ought to know--prognostic and predictive factors. (2013) (37)
- Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): Results from a phase II study (2007) (37)
- Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours (2019) (36)
- Accounting for proximal variants improves neoantigen prediction (2018) (36)
- EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer. (2008) (36)
- Biostatistics Primer: What a Clinician Ought to Know Subgroup Analyses (2010) (36)
- The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). (2012) (36)
- Pemetrexed in Second Line and beyond Small Cell Lung Cancer: A Hoosier Oncology Group Phase II Study (2009) (35)
- Phase I results of RTOG L-0117; a phase I/II dose intensification study using 3DCRT and concurrent chemotherapy for patients with Inoperable NSCLC (2005) (35)
- A Clinical Model to Estimate Recurrence Risk in Resected Stage I Non-Small Cell Lung Cancer (2008) (35)
- Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First‐Line Therapy in Patients with Extensive‐Disease Small Cell Lung Cancer (2019) (33)
- Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment (2021) (33)
- O-103 A comparison of the antitumour efficacy of ZD6474 and gefitinib(Iressa™) in patients with NSCLC: Results of a randomized, double-blind Phase II study (2005) (33)
- The Washington Manual® of Oncology (2007) (32)
- Molecular profile of lung cancer in never smokers (2013) (31)
- An emerging place for lung cancer genomics in 2013. (2013) (31)
- Lung cancer in never smokers: a new hot area of research. (2010) (31)
- Brain Metastases at Presentation in Patients With Non–Small Cell Lung Cancer (2015) (31)
- Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673). (2015) (30)
- Insulin-like growth factor and lung cancer. (2006) (30)
- A Phase II Study of Irinotecan and Carboplatin in Advanced Non-small Cell Lung Cancer with Pharmacogenomic Analysis: Final Report (2006) (30)
- Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies. (2006) (29)
- OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC (2019) (29)
- Time to activate lung cancer clinical trials and patient enrollment: a representative comparison study between two academic centers across the atlantic. (2010) (29)
- Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data (2015) (29)
- Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory Small Cell Lung Cancer. (2019) (29)
- CheckMate 451: A randomized, double-blind, phase III trial of nivolumab (nivo), nivo plus ipilimumab (ipi), or placebo as maintenance therapy in patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC) after first-line platinum-based doublet chemotherapy (PT-DC). (2016) (28)
- Cediranib (AZD2171) for the treatment of recurrent small cell lung cancer (SCLC): A California Consortium phase II study (NCI # 7097) (2008) (28)
- Efficacy and Safety Results From a Phase II, Placebo‐Controlled Study of Onartuzumab Plus First‐Line Platinum‐Doublet Chemotherapy for Advanced Squamous Cell Non–Small‐Cell Lung Cancer (2017) (27)
- Review of Ongoing Clinical Trials in Non-small Cell Lung Cancer: A Status Report for 2009 from the ClinicalTrials.gov Website (2010) (27)
- An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). (2017) (26)
- Cetuximab in Advanced Non-Small Cell Lung Cancer (2004) (26)
- TP53 Mutations and Lung Cancer: Not All Mutations Are Created Equal (2014) (26)
- Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC). (2016) (26)
- Phase 2 Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin with Concurrent Radiation Therapy Followed by Pemetrexed Consolidation in Patients with Favorable-Prognosis Inoperable Stage IIIA/B Non–Small-Cell Lung Cancer (2013) (26)
- Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report. (2003) (26)
- Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC. (2004) (26)
- A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407--Early evaluation of feasibility and toxicity (2008) (24)
- Genomics of squamous cell lung cancer. (2013) (24)
- Randomized, open-label, phase III study of pemetrexed plus carboplatin (PemC) followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab (PCB) followed by maintenance bevacizumab in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). (2013) (23)
- Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer (2019) (23)
- Overcoming resistance to targeted therapy for lung cancer. (2015) (23)
- Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC). (2021) (22)
- Bone metastases in lung cancer. Potential novel approaches to therapy. (2015) (21)
- Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS) (2009) (21)
- Quality of Life Analyses from the Randomized, Open-Label, Phase III PointBreak Study of Pemetrexed-Carboplatin-Bevacizumab followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Sm (2015) (21)
- The proportion of patients with metastatic non-small cell lung cancer potentially eligible for treatment with bevacizumab: a single institutional survey. (2006) (21)
- Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies. (2015) (21)
- Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies (2017) (20)
- Annual Review of Advances in Lung Cancer Clinical Research: A Report for the Year 2009 (2010) (20)
- Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations (2019) (20)
- Clinical applications of The Cancer Genome Atlas project (TCGA) for squamous cell lung carcinoma. (2013) (19)
- Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer. (2005) (19)
- Phase II Trial of S-1 as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer (2011) (18)
- Absence of mutations in the epidermal growth factor receptor (EGFR) kinase domain in patients with mesothelioma. (2009) (18)
- Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer (2005) (18)
- A Phase I Trial of Sunitinib and Rapamycin in Patients with Advanced Non-Small Cell Lung Cancer (2013) (18)
- Novel agents in the treatment of lung cancer: conference summary statement. (2004) (18)
- Genomic Profiling of Lung Adenocarcinoma in Never-Smokers (2021) (17)
- Overcoming chemotherapy resistance in Small Cell Lung Cancer. (2021) (17)
- 7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC) (2015) (17)
- Attack of the clones (2014) (17)
- Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer. (2018) (17)
- Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. (2019) (16)
- Summary Statement Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference Assessing Opportunities for Combination Therapy (2008) (16)
- Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non–small cell lung cancer (2015) (16)
- Esophageal Carcinoma with Celiac Nodal Metastases; Curative or Palliative? (2008) (16)
- ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC. (2020) (16)
- Pemetrexed in patients (pts) with relapsed small cell lung cancer (SCLC): A phase II study from the Hoosier Oncology Group. (2006) (16)
- An open label phase II trial of the Plk1 inhibitor BI 2536, in patients with sensitive relapse small cell lung cancer (SCLC). (2009) (16)
- A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer. (2010) (16)
- Stabilization of disease after targeted therapy in a thymic carcinoma with KIT mutation detected by clinical next-generation sequencing. (2014) (16)
- Devita, Hellman, and Rosenberg's Cancer Principles & Practice of Oncology Review (2020) (16)
- Comprehensive genomic characterization of squamous cell carcinoma of the lung. (2012) (16)
- A randomized phase II study of radiation therapy, pemetrexed, and carboplatin with or without cetuximab in stage III non-small-cell lung cancer. (2006) (16)
- Patupilone for the treatment of recurrent/progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): An open-label phase II study (2008) (16)
- Treatment approaches in patients with advanced non-small cell lung cancer and poor performance status. (2004) (16)
- Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients (Pts) with molecularly selected advanced cholangiocarcinoma (CCA). (2017) (16)
- Clinical trials of antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474 (2006) (15)
- ORAL02.01: Safety and Efficacy of Single‐Agent Rovalpituzumab Tesirine, a DLL3‐Targeted ADC, in Recurrent or Refractory SCLC: Topic: Medical Oncology (2016) (15)
- Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University experience. (2004) (15)
- Is There a Role for Cetuximab in Non–Small Cell Lung Cancer? (2007) (15)
- Phase III study of cisplatin (P) plus etoposide (E) with concurrent chest radiation (XRT) followed by docetaxel (D) vs. observation in patients (pts) with stage III non-small cell lung cancer (NSCLC): An interim toxicity analysis of consolidation therapy. (2006) (15)
- Recent advances and future perspectives in the management of lung cancer. (2005) (15)
- Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (nsNSCLC). (2015) (15)
- Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation. (2002) (15)
- A phase I study of temsirolimus and thoracic radiation in non--small-cell lung cancer. (2014) (14)
- Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC). (2019) (14)
- Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. (2010) (14)
- Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. (2022) (14)
- Influenza vaccination in patients with cancer: an overview. (2010) (14)
- P52.03 Efficacy of Sotorasib in KRAS p.G12C-Mutated NSCLC with Stable Brain Metastases: A Post-Hoc Analysis of CodeBreaK 100 (2021) (13)
- Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. (2012) (13)
- Early Mortality in Patients Undergoing Adjuvant Chemotherapy for Non–Small Cell Lung Cancer (2018) (13)
- A phase I study of bexarotene and rosiglitazone in patients with refractory cancers. (2006) (13)
- Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies (2003) (13)
- Untangling the evolutionary roots of lung cancer (2019) (13)
- Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216). (2022) (13)
- Multi-institutional prospective validation of prognostic mRNA signatures in early stage squamous lung cancer (Alliance). (2020) (13)
- Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. (2006) (13)
- A Phase I Study of Bexarotene and Rosiglitazone in Patients with Refractory Cancers (2008) (13)
- Multicenter Phase II Trial of Motexafin Gadolinium and Pemetrexed for Second-Line Treatment in Patients with Non-small Cell Lung Cancer (2011) (12)
- Irinotecan and carboplatin in metastatic or recurrent NSCLC: an update. (2004) (12)
- Activity of patupilone for the treatment of recurrent or progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): An open-label, multicenter, phase II study (2007) (12)
- Management of patients with non-small cell lung cancer and poor performance status (2003) (12)
- Compassionate use experience with gefitinib in poor performance (PS) patients with advanced non-small-cell lung cancer (NSCLC) treated in an expanded access program (EAP). (2004) (12)
- Novel Agents in the Treatment of Lung Cancer (2004) (12)
- INTERESTing biomarker to select IDEAL patients for epidermal growth factor receptor tyrosine kinase inhibitors: yes, for EGFR mutation analysis, others, I PASS. (2010) (12)
- Next-Generation Sequencing of Lung Cancers: Lessons Learned and Future Directions. (2017) (12)
- Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib. (2021) (12)
- Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer. (2021) (12)
- Pneumocystis pneumonia in a patient with non-small cell lung cancer (NSCLC) treated with pemetrexed containing regimen. (2007) (12)
- Effect of metastatic site on survival in patients with neuroendocrine neoplasms (NENs). An analysis of SEER data from 2010 to 2014 (2020) (11)
- A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104 (2009) (11)
- Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference (2007) (11)
- RNA profiling of cyclooxygenases 1 and 2 in colorectal cancer (2004) (11)
- Annual Review of Advances in Non-small Cell Lung Cancer Research: A Report for the Year 2010 (2011) (11)
- A Phase I Trial of Temsirolimus and Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer (2016) (11)
- Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway (2021) (10)
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma (2022) (10)
- ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC) (2018) (10)
- Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study (2021) (10)
- Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies. (2009) (10)
- Immunogenicity of Influenza Vaccination in Patients With Cancer (2015) (10)
- Phase I study of rubitecan and gemcitabine in patients with advanced malignancies. (2002) (10)
- An analysis of elderly patients (pts) treated on a phase III trial of cisplatin (P) plus etoposide (E) with concurrent radiotherapy (CRT) followed by docetaxel (D) vs observation (O) in pts with stage III non small cell lung cancer (NSCLC) (2007) (9)
- A prospective study on the incidence of delayed nausea and vomiting following administration of carboplatin-containing regimens for treatment of cancer without prophylactic aprepitant. (2008) (9)
- Phase I/II Dose-Finding Study of Crizotinib (CRIZ) in Combination with Erlotinib (E) in Patients (PTS) with Advanced Non-Small Cell Lung Cancer (NSCLC) (2012) (9)
- Recent advances in lung cancer: summary of presentations from the 45th annual meeting of the American Society of Clinical Oncology (2009). (2009) (9)
- 3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC) (2015) (9)
- The Impact of Staging by Positron‐Emission Tomography on Overall Survival and Progression‐Free Survival in Patients With Locally Advanced NSCLC (2018) (9)
- A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer (2021) (9)
- Long non-coding RNA LCAL62 / LINC00261 is associated with lung adenocarcinoma prognosis (2020) (9)
- Toxicity and Response of Pemetrexed Plus Carboplatin or Cisplatin with Concurrent Chest Radiation Therapy for Patients with Locally Advanced Non-small Cell Lung Cancer: A Phase I Trial (2010) (9)
- Paclitaxel (P) plus bevacizumab (B) in patients (pts) with chemosensitive relapsed small cell lung cancer (SCLC): A safety, feasibility and efficacy trial from the Hoosier Oncology Group (2008) (9)
- Delayed nausea and vomiting from carboplatin doublet chemotherapy (2016) (8)
- Initial safety assessment of MAGE-A10c796TCR T-cells in two clinical trials. (2018) (8)
- A Phase I Study of Pegylated Liposomal Doxorubicin and Irinotecan in Patients with Solid Tumors (2009) (8)
- O-183 A phase III study of surgical resection and chemotherapy (paclitaxel/carboplatin) (CT) with or without adjuvant radiation therapy (RT) for resected stage III non-small cell lung cancer (NSCLC): CALGB 9734 (2003) (8)
- Comprar Devita, Hellman, And Rosenberg's Cancer. Principles And Practice Of Oncology. Review 4th Ed. | Ramaswamy Govindan | 9781496310804 | Lippincott Williams & Wilkins (2016) (8)
- A randomized phase 2 study of abemaciclib versus docetaxel in patients with stage IV squamous non-small cell lung cancer (sqNSCLC) previously treated with platinum-based chemotherapy. (2016) (8)
- Management of patients with advanced non-small cell lung cancer: role of gefitinib (2010) (8)
- Phase II trial of sequential bevacizumab (B), erlotinib (E) and chemotherapy for first line treatment of clinical stage IIIB or IV non-small cell lung cancer (NSCLC) (2008) (8)
- Molecularly targeted therapies in locally advanced non-small-cell lung cancer. (2013) (8)
- Adjuvant Chemotherapy for Patients with T2N0M0 Non-small-cell Lung Cancer (NSCLC). (2015) (8)
- Phase I/II dose-finding study of crizotinib (CRIZ) in combination with erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC). (2012) (8)
- Vaccines and Immunotherapy for Non-small Cell Lung Cancer (2010) (8)
- Summary of Presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010) Focus on Tumor Biology and Biomarkers Related to Lung Cancer (2011) (8)
- A phase II study of intravenous (IV) milataxel (M) for the treatment of non-small cell lung cancer (NSCLC) refractory to platinum-based therapy. (2006) (8)
- Treatment of patients excluded from Eastern Cooperative Oncology Group 4599 and AVAiL studies: focus on brain metastasis and squamous histology. (2008) (8)
- A phase I study of docetaxel and bexarotene. (2004) (8)
- Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO) (2021) (8)
- Locally Advanced, Unresectable Non–Small-Cell Lung Cancer (2007) (8)
- A phase II study of cisplatin, 5 fluorouracil (5-FU), radiation (RT) and celecoxib in patients with resectable esophageal cancer (EC): Updated results from the Hoosier Oncology Group (HOG) study (2004) (8)
- Small cell, big problem! Stem cells, root cause? (2008) (7)
- Whole Exome Sequencing of Highly Aggregated Lung Cancer Families Reveals Linked Loci for Increased Cancer Risk on Chromosomes 12q, 7p, and 4q (2019) (7)
- Response to bortezomib (velcade) in a case of advanced bronchiolo-alveolar carcinoma (BAC). A case report. (2006) (7)
- Ongoing phase II study of pemetrexed plus carboplatin or cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/b non-small cell lung cancer: Interim update. (2010) (7)
- The SELECT trial: A multicenter phase II trial of adjuvant erlotinib (E) in patients with resected, early-stage non-small cell lung cancer (NSCLC) and confirmed mutations in the epidermal growth factor receptor (EGFR). (2011) (7)
- A Phase I Study of Docetaxel and Bexarotene (2008) (7)
- Systemic Treatment of Brain Metastases. (2017) (7)
- Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway (2022) (7)
- Genomic landscape of squamous cell carcinoma of the lung. (2013) (7)
- In Their Own WordsIn Their Own WordsIn Their Own WordsIn Their Own Words (2017) (7)
- Abstract CT008: Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100 (2022) (7)
- B5-01: Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023 (2007) (7)
- 9007 Randomized, double-blind phase II/III study of first-line paclitaxel (P) plus carboplatin (C) in combination with vorinostat or placebo in patients with advanced non-small-cell lung cancer (NSCLC) (2009) (7)
- ALCHEMIST: a clinical trial platform to bring genomic discovery and molecularly targeted therapies to early-stage lung cancer. (2015) (7)
- Everolimus, an mTOR inhibitor, in combination with docetaxel for second- or third-line therapy of advanced-stage non-small cell lung cancer: A phase II study. (2011) (7)
- Practical issues in the management of the patient with small cell lung cancer. (1997) (7)
- 1257O Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib) (2020) (6)
- [A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer]. (2010) (6)
- The Mystic Role of Tumor Mutational Burden in Selecting Patients With Lung Cancer for First-Line Immunotherapy. (2020) (6)
- Mutational Events in Lung Cancer: Present and Developing Technologies (2018) (6)
- Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer (2022) (6)
- Establishment of Novel Neuroendocrine Carcinoma Patient-Derived Xenograft Models for Receptor Peptide-Targeted Therapy (2022) (6)
- Malignant pleural mesothelioma. (2015) (6)
- Abstract CT125: A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broadde novoanti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer (2018) (6)
- Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC). (2018) (6)
- Thymic malignancies. (2010) (6)
- Irinotecan and carboplatin in metastatic or recurrent non-small-cell lung cancer. (2003) (6)
- BRCAness in non-small cell lung cancer (NSCLC). (2014) (6)
- NCCN Non – Small Cell Lung Cancer Clinical Practice Guidelines in Oncology (2010) (6)
- Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in patients with advanced solid tumors harboring KRAS p.G12C mutation (CodeBreak 101). (2020) (6)
- A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations (2021) (5)
- Phase II trial of bexarotene capsules in patients with non-small-cell lung cancer (NSCLC) who have failed at least 2 prior systemic therapies for Stage IIIB/IV disease (2005) (5)
- Point of care tobacco treatment sustains during COVID-19, a global pandemic (2021) (5)
- Mastering the Complex Targeted Therapy for Non-small Cell Lung Cancer. (2020) (5)
- Clonal evolution: multiregion sequencing of esophageal adenocarcinoma before and after chemotherapy. (2015) (5)
- Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer. (2008) (5)
- Phase II study of pemetrexed (P) plus carboplatin (Cb) or cisplatin (C) with concurrent radiation therapy followed by pemetrexed consolidation in patients (pts) with favorable-prognosis inoperable stage IIIA/B non-small cell lung cancer (NSCLC). (2012) (5)
- Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreaK 101). (2021) (5)
- Clinician Perspectives on Current Issues in Lung Cancer Drug Development (2016) (5)
- Circulating cell-free tumor DNA (cfDNA) testing in small cell lung cancer. (2016) (5)
- Exploratory analyses of efficacy and safety of pemetrexed (Pem) plus bevacizumab (Bev) and bev alone as maintenance therapy (MT) in patients (Pts) with stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC). (2013) (5)
- Liquid biopsies for residual disease and recurrence. (2021) (5)
- PD3-3-8: A phase II study of continuous daily sunitinib dosing in patients with previously-treated advanced non-small cell lung cancer (NSCLC) (2007) (5)
- Interim results from a phase Ib/II study of pepinemab in combination with avelumab in advanced NSCLC patients following progression on prior systemic and/or anti-PDx therapies. (2020) (4)
- NEURO/MEDICAL ONCOLOGY (2013) (4)
- Overcoming Chemotherapy Resistance in SCLC (2021) (4)
- Recent Advances in Lung Cancer: Summary of Presentations from the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2011 (2012) (4)
- Abstract P05-01: A phase 1b study evaluating the safety and efficacy of sotorasib, a KRASG12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-Mutated Solid Tumors (2021) (4)
- An open-label, phase 1b study of NEO-PV-01 with pembrolizumab plus chemotherapy in patients with advanced or metastatic nonsquamous non-small cell lung cancer. (2018) (4)
- Phase I Study of Accelerated Hypofractionated Proton Therapy and Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) (2018) (4)
- Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients (2021) (4)
- Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC). (2020) (4)
- Targeting Resistance to Targeted Therapies: Combating a Resilient Foe (2018) (4)
- A phase II study of carboplatin, etoposide and exisulind in patients with extensive stage small cell lung cancer: CALGB 30104 (2005) (4)
- Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung C (2015) (4)
- Summary of presentation from the targeted therapy in lung cancer meeting. (2011) (4)
- Targeted Therapy in Lung Cancer: Lessons Learned from Past Experiences (2011) (4)
- Open-Sourced CIViC Annotation Pipeline to Identify and Annotate Clinically Relevant Variants Using Single-Molecule Molecular Inversion Probes (2019) (4)
- Summary of the proceedings from the 10th annual meeting of molecularly targeted therapy in non-small cell lung cancer. (2010) (4)
- Bone metastases in non-small cell lung cancer: a narrative review (2021) (4)
- Locally Advanced Non-Small-Cell Lung Cancer (2004) (4)
- 359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results (2020) (4)
- Third-line chemotherapy with gemcitabine or docetaxel in patients with advanced non-small cell lung cancer (NSCLC) (2005) (4)
- Radiation-induced myonecrosis presenting as a subcutaneous mass after combined modality therapy for non-small cell lung cancer. (2007) (3)
- One more fallen star--ZODIAC and its implications. (2010) (3)
- NLG-0301: An open-label, randomized phase 2B active control study of second-line tergenpumatucel-L immunotherapy versus docetaxel in patients with progressive or relapsed non-small cell lung cancer (NSCLC). (2014) (3)
- Efficacy and safety of alectinib in ALK+ non-small-cell lung cancer (NSCLC): Pooled data from two pivotal phase II studies (NP28673 and NP28761). (2016) (3)
- Phase II trial of R-(-)-gossypol acetic acid (NSC 726190, AT-101) in patients with recurrent extensive stage small cell lung cancer (ES-SCLC). (2010) (3)
- Molecular Basis of Lung Cancer (2014) (3)
- Clinical-pathologic conference in general thoracic surgery: Cardiac lymphoma. (2005) (3)
- PS01.58: A Phase 3 Trial of Nivolumab, Nivolumab Plus Ipilimumab, or Placebo Maintenance for Extensive‐Stage SCLC After First‐Line Chemotherapy: Topic: Medical Oncology (2016) (3)
- A phase II study of topotecan and docetaxel in patients with sensitive relapse small cell lung cancer (2008) (3)
- O-084 Phase 2 study of bortezomib±docetaxel in advanced non-smallcell lung cancer (NSCLC) (2005) (3)
- PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery (2022) (3)
- Abstract A084: DENALI: a 3-arm double-blind randomized phase 2 study of carboplatin, pemetrexed, and placebo (CPP) versus carboplatin, pemetrexed, and either 1 or 2 truncated courses of demcizumab (CPD) in patients with non-squamous non-small cell lung cancer (NSCLC) (2018) (3)
- TRAC(ERx)-ing lung cancer evolution. (2017) (3)
- Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer. (2022) (3)
- Distinctive characteristics of extrapulmonary small cell carcinoma: A Surveillance Epidemiology and End Results (SEER) analysis (2008) (3)
- Clinical roundtable monograph: Recent advances in taxanes for the first-line treatment of advanced non-small cell lung cancer. (2012) (3)
- Phase II Study of Continuous Daily Sunitinib Dosing in Patients with Previously Treated Advanced Non–Small-Cell Lung Cancer (NSCLC) (2007) (3)
- Cancer gene sequencing: ethical challenges and promises. (2012) (3)
- Phase I study of bexarotene and rosiglitazone in patients with refractory cancers (2005) (3)
- Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy in subjects with extensive-disease small cell lung cancer (ED-SCLC) (2016) (3)
- OA11.03 A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLC (2021) (3)
- P1.07-035 Circulating Cell-Free Tumor DNA (cfDNA) Testing in Small Cell Lung Cancer: Topic: Molecular Changes (2017) (3)
- Comprar The Washington Manual of Oncology 2/e | Ramaswamy Govindan | 9780781784023 | Lippincott Williams & Wilkins (2007) (3)
- Hope without hype: EML4-ALK inhibition for treatment of lung cancer. (2011) (3)
- Preliminary results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC. (2019) (3)
- OA01.06 Safety, Efficacy, and Pharmacokinetics of AMG 510, a Novel KRASG12C Inhibitor, in Patients with Non-Small Cell Lung Cancer (2019) (3)
- MA07.01 Updated Pooled Analysis of CNS Endpoints in Two Phase II Studies of Alectinib in ALK+ NSCLC (2017) (3)
- O-106 A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC) (2005) (3)
- Optimising therapy for EGFR-addicted NSCLC: just the start. (2012) (3)
- Chemotherapy: Continued lack of progress in SCLC (2010) (3)
- Increased Reach and Effectiveness With a Low-Burden Point-of-Care Tobacco Treatment Program in Cancer Clinics. (2022) (2)
- Adjuvant chemotherapy for lung cancer: cisplatin doublets only? (2008) (2)
- PD5-2-4: Phase I/II results of RTOG L-0117; a phase I/II dose intensification study using 3DCRT and concurrent chemotherapy for patients with inoperable NSCLC (2007) (2)
- A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors (2020) (2)
- Chemotherapy for metastatic NSCLC: current status and future direction (2005) (2)
- Drug delivery and toxicity of adjuvant chemotherapy for non-small cell lung cancer (NSCLC): Washington University experience (2007) (2)
- Clinical benefit with compassionate use gefitinib in a subset of non-small-cell lung cancer (NSCLC) patients with the bronchoalveolar (BAC) subtype treated during an expanded access program (EAP) (2004) (2)
- Developmental pathways are epigenetically reprogrammed during lung cancer brain metastasis. (2022) (2)
- Improving survival for metastatic non-small cell lung cancer: A SEER database analysis from 1990 to 2005. (2009) (2)
- Phase I Study of Accelerated Hypofractionated Proton Therapy and Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer. (2022) (2)
- PDXNet Portal: Patient-Derived Xenograft model, data, workflow, and tool discovery (2021) (2)
- Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation. (2021) (2)
- Distinctive characteristics of non-small cell lung cancer in the young: A SEER analysis of patients under 40 years old (2007) (2)
- Abstract 73: A personal neoantigen vaccine NEO-PV-01 in combination with chemotherapy and pembrolizumab induces broad de novo immune responses in first-line non-squamous NSCLC: Associations with clinical outcomes (2021) (2)
- Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignancies. (2021) (2)
- Prevalence, clinical risk factors and outcomes of patients with lung cancer presenting with brain metastases. (2016) (2)
- A phase 2, fast real-time assessment of combination therapies in immuno-oncology trial in patients with advanced non-small cell lung cancer (FRACTION-lung) (2016) (2)
- Efficacy and safety of gefitinib in chemo-naive patients with non-small cell lung cancer (NSCLC) in an expanded access program (EAP) (2005) (2)
- Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer (2022) (2)
- Efficacy of vinorelbine in the second-line setting and beyond in non-small cell lung cancer. (2007) (2)
- The era of big trials is over. (2013) (2)
- What a Clinician Ought to Know—Prognostic and Predictive Factors (2013) (2)
- A pooled analysis of concurrent chemoradiotherapy (CCRT) for patients with stage III non-small cell lung cancer (NSCLC) who participated in U.S. Cooperative Group Trials: comparing the outcomes of elderly to younger patients (pts) (2016) (2)
- 278 Phase I clinical trial evaluating the safety of ADP-A2M10 SPEAR T-cells in patients with MAGE-A10+ advanced non-small cell lung cancer (2020) (2)
- Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. (2023) (2)
- Barriers for accrual to clinical trials in adult patients (pts) with thoracic malignancies. (2006) (2)
- A phase I study of pemetrexed plus carboplatin or cisplatin with concurrent chest radiation therapy (CRT) for patients with locally advanced non-small cell lung cancer (LANSCLC). (2016) (2)
- Second-line therapy for esophageal cancer (2007) (2)
- O-115 Induction chemotherapy with gemcitabine-containing regimensin stage I–II non-small cell lung cancer (NSCLC): Initial results of the GINEST* Project (2005) (2)
- Summary of presentations from the 46th Annual Meeting of the American Society of Clinical Oncology: focus on non-small cell lung cancer (2010). (2011) (2)
- Efficacy and Safety Results From a Phase 2, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous-Cell Non-Small Cell Lung Cancer (sq NSCLC) (2014) (2)
- Best of the month: a roundup of articles published in recent months. (2010) (2)
- Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts (2021) (2)
- A phase I trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer. (2006) (2)
- P-603 Phase I results of RTOG L-0117; a phase i/II dose intensificationstudy using 3DCRT and concurrent chemotherapy for patients with inoperable NSCLC (2005) (2)
- Adjuvant Therapy With EGFR Tyrosine Kinase Inhibitors: Tempering Great Expectations With Realism. (2021) (2)
- Impact of the Comprehensive Health Enhancement Support System (CHESS), an interactive computer support system (ICSS) on non small cell lung cancer (NSCLC) survival: A randomized study comparing CHESS with the internet (2008) (1)
- LBA48ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC) (2017) (1)
- CASE 3. Benign pleural nodules in a patient with esophageal cancer. (2006) (1)
- MO01.31 Durability of Clinical Benefit and Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Sotorasib, a KRAS(G12C) Inhibitor (2021) (1)
- A phase I, open-label, study of GSK2879552, a lysine-specific demethylase 1 (LSD1) inhibitor, in patients with relapsed/refractory small cell lung carcinoma (SCLC) (2016) (1)
- Cancer of unknown primary (2008) (1)
- Abstract CT209: A phase I study with the oral pan-CDK inhibitor BAY 1000394 in patients with advanced stage small cell lung or ovarian cancer (2014) (1)
- A phase II study of cisplatin, 5 fluorouracil (5-FU), radiation (RT) and celecoxib in patients with resectable esophageal cancer (EC): Updated results from the Hoosier Oncology Group (HOG) study. (2004) (1)
- 802 Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint blockade (2020) (1)
- Clinical predictive model for brain metastasis at presentation in patients with non-small-cell lung cancer (NSCLC). (2013) (1)
- Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC. (2020) (1)
- FP07.13 Clinical Characteristics and Outcomes in Patients With KRAS G12C Mutated Non-Small Cell Lung Cancer (2021) (1)
- Biomarker-Driven Staging-Are We There Yet? (2019) (1)
- Summary of presentations from the 46th annual meeting of the American Society of Clinical Oncology (2010): focus on supportive care issues related to lung cancer. (2011) (1)
- P1.16-47 Adjuvant Targeted Therapy Following Standard Adjuvant Therapy for Resected NSCLC: An Initial Report from ALCHEMIST (Alliance A151216) (2018) (1)
- Poster SessionP2.03a-003 Belinostat in Combination with Carboplatin and Paclitaxel in Patients with Chemotherapy-Naive Metastatic Lung Cancer (NSCLC): Topic: Clinical Trials (2017) (1)
- 48MO Phase I study of AMG 757, a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer (SCLC) (2021) (1)
- Abstract A52: Role of circulating tumor DNA (ctDNA) from liquid biopsy in early-stage NSCLC resected lung tumor investigation (LIBERTI) (2020) (1)
- Summary of presentations from the 46th annual meeting of the American Society Of Clinical Oncology (2010): focus on developmental therapeutics related to lung cancer. (2011) (1)
- Time to move beyond clinical and pathologic classification of BAC. (2010) (1)
- A phase II trial of gefitinib in patients with chemosensitive and chemorefractory relapsed neuroendocrine cancers. A Hoosier Oncology Group Trial (2005) (1)
- Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials. (2018) (1)
- Abstract 2136: RegTools: Integrative analysis of genomic and transcriptomic data to identify splice altering mutations across 35 cancer types (2020) (1)
- Use of the internet for self-education by adults with cancer (2008) (1)
- Non-small cell lung cancer in the new millennium: The effect of FDG-PET on stage distribution. (2006) (1)
- Targeting KRAS G12C mutation in lung adenocarcinoma. (2021) (1)
- MA14.03 Genomic Profiles and Potential Determinants of Response and Resistance in KRAS p.G12C-mutated NSCLC Treated With Sotorasib (2021) (1)
- Toxicity and Response of Pemetrexed Plus Carboplatin or Cisplatin with Concurrent Chest Radiation Therapy (CRT) for Patients with Locally Advanced Non–small-cell Lung Cancer (LANSCLC): A Phase I Trial (2009) (1)
- PD3-1-8: Motexafin Gadolinium (MGd) is active as a single agent in advanced non-small-cell lung cancer (NSCLC) patients who failed platinum-based chemotherapy: preliminary results of a phase II trial (2007) (1)
- Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel (Taxoprexin) in resistant solid tumor malignancies (2006) (1)
- Clinical benefit with compassionate use gefitinib in a subset of non-small-cell lung cancer (NSCLC) patients with the bronchoalveolar (BAC) subtype treated during an expanded access program (EAP). (2004) (1)
- The impact of neoadjuvant chemotherapy and surgery on quality of life (QL) in patients with early stage NSCLC: A prospective analysis of the GINEST project (2005) (1)
- Final results of a phase II trial of bexarotene capsules as 3rd or subsequent line therapy in patients with advanced non-small cell lung cancer (NSCLC). (2006) (1)
- NCCN Small Cell Lung Cancer Clinical Practice Guidelines in Oncology (2013) (1)
- Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway (2021) (1)
- Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer (2019) (1)
- NCCN Non – Small Cell Lung Cancer , Version 1 . 2015 Clinical Practice Guidelines in Oncology (2014) (1)
- A Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer (2021) (1)
- 1247P Management of infusion-related reactions (IRRs) in patients receiving amivantamab (2021) (1)
- Late-breaking abstract: Is primary tumour standardized uptake value (SUV) an independent prognostic factor for non small cell lung cancer (NSCLC)? A meta-analysis based on individual data (2011) (1)
- Sunitinib plus Erlotinib for the Treatment of Metastatic Non—Small-Cell Lung Cancer: A Novel VEGFR—EGFR Co-Inhibition Treatment Strategy (2008) (1)
- The role of docetaxel in N2 locally advanced non-small-cell lung cancer. (2005) (1)
- An open-label, phase Ib study of NEO-PV-01 + adjuvant with nivolumab in patients with melanoma, non-small cell lung carcinoma, or transitional cell carcinoma of the bladder. (2017) (1)
- Phase I study of weekly docetaxel and topotecan in the treatment of advanced solid tumors. (2004) (1)
- A Phase I trial of weekly docetaxel and topotecan for solid tumors (2008) (1)
- Crizotinib: an orphan drug for treating non-small-cell lung cancer (2015) (1)
- MA 10.02 Nab-Paclitaxel + Durvalumab as Second- or Third-Line Treatment of Advanced NSCLC: Results from ABOUND.2L+ (2017) (1)
- Prognostic impact of malignant pleural effusion in patients with stage M1b non-small cell lung cancer. (2010) (1)
- Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: Washington University experience: P1-035 (2007) (1)
- P2.15-C Phase 1 Trial Evaluating Safety, Efficacy, and PK of AMG 510, a Novel KRASG12C Inhibitor, in Non-Small Cell Lung Cancer (2019) (1)
- P1.05-001 Creation and Early Validation of Prognostic miRNA Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium: Topic: Translational Research and Biomarkers (2017) (1)
- 6525 POSTER Phase II study investigating the efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC) (2007) (1)
- MO01.30 Trial in Progress: A Phase 1b Study of Sotorasib, a KRAS (G12C) Inhibitor, in Combination with other Anticancer Therapies in Patients with Advanced Solid Tumors Harboring KRAS p.G12C Mutation (CodeBreaK101) (2021) (1)
- Abstract 4176: Familial lung cancer exhibits multiple novel linked haplotypes within pedigrees (2019) (1)
- Two phase I/II open label clinical trials evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 or MAGE-A10 in subjects with stage IIIb or stage IV non-small cell lung cancer (NCT02588612/NCT02592577). (2017) (1)
- Stage III pulmonary large cell neuroendocrine carcinoma (LNEC). (2016) (1)
- Real-world utilization of targeted therapy in cancer treatment. (2011) (1)
- Characteristics of 1q amplification in adenocarcinoma of the lung (LUAD). (2014) (1)
- Open-label phase II study of S-1 as second-line therapy for patients with advanced non-small cell lung cancer (NSCLC). (2010) (1)
- Targeted Therapy of Non-Small-Cell Lung Cancer (2006) (1)
- A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study of Onartuzumab (METMAB) in Combination with Paclitaxel + Cisplatin (or Carboplatin) as First-Line Treatment for Patients (PTS) With Stage IIIB or IV Squamous Non-Small Cell Lung Cancer (NSCLC) (2012) (1)
- Somatic mutations in mismatch repair pathway genes in non-small cell lung cancer. (2016) (1)
- INDUCTION AND ADJUVANT THERAPY FOR OPERABLE NON–SMALL CELL LUNG CANCER (2008) (1)
- Phase I study combining MLN8237 with nab-paclitaxel in patients with advanced solid malignancies. (2014) (1)
- How far has lung cancer treatment progressed (2012) (1)
- Barriers for accrual to clinical trials in adult patients (pts) with non-small cell lung cancer: P1-250 (2007) (1)
- 9081 POSTER Network Meta-analysis of Second and Third-line Treatments on Overall Response and Overall Survival in Patients With Metastatic Non-small Cell Lung Cancer (2011) (1)
- Abstract LB001: Identifying MAGE-A4-positive tumors for SPEAR T-cell therapies in HLA-A*02-eligible patients (2022) (0)
- 68. Integrative analysis of genomic and transcriptomic data using RegTools to identify splice-altering mutations within bulk (2022) (0)
- Clinician Perspectives on Barriers and Enablers to Implementing an Inpatient Oncology Early Warning System: A Mixed-Methods Study. (2023) (0)
- Molecular Pathogenesis and Therapeutic Targets for Specific Cancers: Molecular Basis of Lung Cancer (2015) (0)
- 130 POSTER Phase II trial of Sequenced Bevacizumab and Erlotinib with Bevacizumab and Chemotherapy for 1st Line Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) (2006) (0)
- Mo1151: SLEEP BEHAVIORS, GENETIC PREDISPOSITIONS, AND RISK OF ESOPHAGEAL CANCER (2022) (0)
- Non-small cell lung cancer. (2008) (0)
- Use of chemotherapy for patients with stage IV non-small cell lung cancer. (2015) (0)
- A pilot study of nintedanib in molecularly selected patients with advanced non-small cell lung cancer (NSCLC) (NCT02299141). (2020) (0)
- P14.19 CD8α-Enhanced NY-ESO-1-Specific TCR T Cells (GSK3901961) in HLA-A*02 Patients with NSCLC: Master Protocol Substudy 1 (2021) (0)
- Randomized, open-label, phase III study of pemetrexed plus carboplatin followed by maintenance pemetrexed (Arm A) versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab (Arm B) in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). (2013) (0)
- Malignant Pleural MesotheliomaPractice Guidelines in Oncology (2012) (0)
- Lung Cancer Takeaways from ASCO 2014 (2014) (0)
- Epidermal Growth Factor Receptor , Human Epidermal Growth Factor Receptor 2 , and Human Epidermal Growth Factor Receptor 3 (2013) (0)
- Key Lung Cancer Takeaways from ASCO 2015 (2015) (0)
- Distinctive characteristics of non-small cell lung cancer in younger patients: A national cancer database (NCDB) analysis of patients under 40 years old (1998–2003) (2007) (0)
- Abstract 848: Sleep behaviors and risk of lung cancer in the UK Biobank (2021) (0)
- Effect of primary tumor size in patients with metastatic non-small cell lung cancer (NSCLC). (2013) (0)
- The Role of Surgery in Stage III Non-Small-Cell Lung Cancer (2008) (0)
- ASCO 2012 Report: Lung Cancer (2012) (0)
- Current and Upcoming Lung Cancer Research (2011) (0)
- Clonal Hematopoiesis and Risk of Incident Lung Cancer (2022) (0)
- Summary report from the 13(th) Annual Targeted Therapies of the Treatment of Lung Cancer Meeting. (2014) (0)
- Pemetrexed maintenance with or without pembrolizumab in non-squamous non-small cell lung cancer: A cross-trial comparison of KEYNOTE-189 versus PARAMOUNT, PRONOUNCE, and JVBL. (2020) (0)
- 22. Standardization and systematization of somatic variant refinement using a standard operating procedure and deep learning (2019) (0)
- P2.03a-002 Patterns of Chemotherapy Use and Overall Survival (OS) of Patients with Stage IV Squamous Lung Cancer (SCC): Topic: Clinical Trials (2017) (0)
- Best of the month: A round up of articles published in recent months. (2011) (0)
- P77.04 PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors (2021) (0)
- P1.01-70 Efficacy and Safety of Second- or Third-Line Nab-Paclitaxel + Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+) (2018) (0)
- 62INRECLASSIFYING LUNG CANCER AND MOLECULAR DIAGNOSTIC. (2014) (0)
- Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint inhibitors. (2022) (0)
- GOVINDAN: OUTSIDE THE BOX: Decoding the Mysteries of Life: From an Ancient Man to a Modern Disease (2010) (0)
- Safety and resource use in the PROCLAIM study comparing 2 regimens of concurrent chemoradiation followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer (NSCLC). (2016) (0)
- Management of patients with advanced NSCLC without actionable mutations: A simulation-based assessment of medical oncologists. (2018) (0)
- P1.01-73 An Explorative Analysis of Pemetrexed +/- Pembrolizumab Maintenance from KEYNOTE-189 Versus PARAMOUNT, PRONOUNCE, and JVBL (2019) (0)
- The articles in this supplement should be viewed more as meeting reports than as exhaustive and comprehensive review articles. Introduction. (2012) (0)
- MicroRNA landscape in non-small cell lung cancer (NSCLC). (2014) (0)
- 表皮生长因子/HER2抑制剂在非小细胞肺癌患者治疗中的作用综述 (2010) (0)
- Phase I study of pegylated liposomal doxorubicin (PLD) and irinotecan (I) in patients with solid tumors. (2006) (0)
- Contents Vol. 55, 2009 (2009) (0)
- Proceedings from the Ninth Annual Targeted Therapies in Lung Cancer Symposium. (2009) (0)
- P1.04-23 Expression of Emerging Immunotherapy Targets in Early-Stage Squamous Lung Carcinoma (2018) (0)
- P09.26 Cause of Death in Patients with Squamous Cell Lung Cancer (SCC) Treated with Surgery (2021) (0)
- A roundup of recently published articles relevant to thoracic oncology. (2011) (0)
- 37. Epigenetic reprogramming of brain development pathways during non-small cell lung cancer metastasis to brain (2022) (0)
- Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium. (2009) (0)
- Abstract 1118: Absence of mouse-specific tumor evolution in patient-derived cancer xenografts (2020) (0)
- Erlotinib for European Patients with Advanced Lung Cancer (2012) (0)
- Dacomitinib Effective for Non–Small-Cell Lung Cancer (2012) (0)
- ERCC1 Expression Is Not Predictive in Lung Cancer (2013) (0)
- CLINICAL UTILITY OF ROUTINELY ADDING POSITRON EMISSION TOMOGRAPHY (PET) TO COMPUTER TOMOGRAPHY (CT) AND ENDOSCOPIC ULTRASOUND (EUS) IN THE INITIAL STAGING OF ESOPHAGEAL CARCINOMA: THE WASHINGTON UNIVERSITY IN ST. LOUIS EXPERIENCE (2006) (0)
- Fibulin-3: A Biomarker for Pleural Mesothelioma (2012) (0)
- eP055: The Clinical Genome Resource (ClinGen) Somatic Cancer Clinical Domain Working Group (2022) (0)
- Lung cancer in never-smokers: A single institutional experience. (2006) (0)
- Role of Next-Generation Sequencing Technologies (2013) (0)
- How Do I Treat... ...a Patient with Newly Diagnosed Metastatic Lung Cancer (2010) (0)
- Comprar Manual Washington De Oncología 3ª Ed. | Ramaswamy Govindan | 9788416353460 | Wolters Kluwer España (2016) (0)
- Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer (NSCLC) patients. (2020) (0)
- Advanced NSCLC: Finding the right prescription for oncologist education. (2014) (0)
- 364 A personal neoantigen vaccine NEO-PV-01 in combination with chemotherapy and pembrolizumab induces broad de novo immune responses in first line, non-squamous NSCLC (2020) (0)
- Prostaglandins and COX-2: Role in Antiangiogenic Therapy (2007) (0)
- The impact of staging by positron emission tomography (PET) on overall survival (OS) and progression-free survival (PFS) in the phase III PROCLAIM study (2016) (0)
- Abstract LB-053: Familial studies identify variants in the E2A transcription factor as putative risk factors for lung cancer (2019) (0)
- My Take on Molecular Testing in Lung Cancer: The New Guidelines for EGFR and ALK Testing (2013) (0)
- Best Lung Cancer Papers, 2013 (2014) (0)
- Prognostic impact of tumor (T) and lymph node (N) status in patients with metastatic non-small-cell lung cancer (NSCLC). (2013) (0)
- Subject Index Vol. 55, 2009 (2009) (0)
- Imaging , functional evaluation and staging for lung cancer patients (2011) (0)
- Abstract 1192: The Clinical Genome Resource (ClinGen) somatic cancer clinical domain working group (2022) (0)
- Systemic Therapy Options for Non–Small-Cell Lung Cancer in Patients with a Poor Performance Status (2007) (0)
- MA06.10 A Pooled Analysis Comparing the Outcomes of Elderly to Younger Patients on NCTN Trials of Concurrent CCRT for Stage 3 NSCLC (2017) (0)
- Epithelial-mesenchymal transition and brain metastasis in non-small cell lung cancer (2008) (0)
- Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a decade of progress and hopeful future. (2015) (0)
- In response. (2013) (0)
- FP07.11 Circulating Tumor DNA (ctDNA) Clearance as a Biomarker in Patients With Locally Advanced NSCLC Following Chemoradiation (2021) (0)
- Efficacy and Safety of Second- or Third-Line Nab-Paclitaxel plus Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+) (2018) (0)
- P1.05-027 Novel Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma: A Study by the SPECS Lung Consortium: Topic: Translational Research and Biomarkers (2017) (0)
- FDG uptake as a predictor of outcome in stage I non-small cell lung cancer. (2006) (0)
- Presentation of non-small cell lung cancer (NSCLC) in octogenarians. (2006) (0)
- 8. Integrating genomic and transcriptomic data to identify splice altering mutations across 35 cancer types (2020) (0)
- Comprar Cancer : Principles and Practice of Oncology Review , 3/e | Ramaswamy Govindan MD | 9781451116397 | Lippincott Williams & Wilkins (2012) (0)
- Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100. (2023) (0)
- OA13.01 SPECS2 Lung Cancer Consortium Prospective Multicenter Validation of Prognostic Signature for Early Stage Squamous Lung Cancer (2019) (0)
- OA19.01 A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium (2017) (0)
- 3100 Phase Ib/II study of the pan-cyclin-dependent kinase (CDK) inhibitor roniciclib (BAY 1000394) in combination with chemotherapy as first-line therapy in subjects with extensive disease small cell lung cancer (ED-SCLC) (2015) (0)
- Summary of Presentations from the Ninth Annual Targeted Therapies in Lung Cancer Symposium (2009) (0)
- Insulin-Like Growth Factor and Lung Cancer (Pathway of the Month) (2006) (0)
- Phase I study of weekly docetaxel and topotecan in the treatment of advanced solid tumors (2004) (0)
- Newly approved drug effective against lung cancer caused by genetic mutation (2021) (0)
- An international comparison of barriers in opening oncology clinical trials. (2016) (0)
- Routine PET Does Not Alter Nodal Staging in Patients Undergoing EUS-FNA for Esophageal Cancer (2008) (0)
- Abstract CT204: A phase 1/2 study of VS-6766 in combination with sotorasib in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC) (RAMP 203) (2022) (0)
- How do I treat … a patient with newly diagnosed metastatic non-small-cell lung cancer? (2010) (0)
- Outcomes of resected stage 1 non-small cell lung cancer (NSCLC) in patients (Pts) aged 70 years and older (2005) (0)
- nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+) (2021) (0)
- MS 02.01 Lung Cancer Genomics (2017) (0)
- Complications of Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer (2007) (0)
- Key Takeaways from the AACR Annual Meeting (2014) (0)
- OA05.03 Single-Agent Rovalpituzumab Tesirine, a Delta-Like Protein 3 (DLL3)-Targeted Antibody-Drug Conjugate (ADC), in Small-Cell Lung Cancer (SCLC) (2017) (0)
- Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK plus Non-Small-Cell Lung Cancer (NSCLC) (2017) (0)
- Genomics of lung cancer (2016) (0)
- Second-line systemic therapy for esophageal cancer (2008) (0)
- Development of a precision oncology single molecule molecular inversion probe (smMIP) panel using a community-consensus approach (2018) (0)
- A phase II trial of motexafin gadolinium (MGd) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum-based chemotherapy: Preliminary results of stage 1 (2007) (0)
- Abstract B53: Multicenter phase Ib study of the safety and efficacy of palifosfamide plus carboplatin/etoposide (PaCE) in patients with small cell lung cancer or other selected cancers. (2011) (0)
- Abstract CT181: Clinical validation of plasma cell-free DNA (cfDNA) sequencing in the phase 2 trial of sotorasib in patients (pts) withKRASp.G12C mutated NSCLC (2021) (0)
- Decoding the mysteries of life: from ancient man to modern disease (2010) (0)
- A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer A C (2021) (0)
- Prognostic value of positron emission tomography in resected stage I non-small cell lung cancer: A2-05 (2007) (0)
- P3.02a-016 Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK+ Non-Small-Cell Lung Cancer (NSCLC) (2017) (0)
- Recent Advances in the Management of Brain Metastases in Non-Small Cell Lung Cancer (2007) (0)
- New insights into the molecular profile of lung adenocarcinoma and implications for therapy (2015) (0)
- Transcriptome sequencing reveals altered long intergenic non-coding RNAs in lung cancer (2014) (0)
- Trial in progress: A phase 1, multicenter, open-label, dose-exploration and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of AMG650 in subjects with advanced solid tumors. (2021) (0)
- Cancer genome sequencing - Clinical implications: Slides (2015) (0)
- MA16.02 Prospective Clinical Validation of the InVisionFirst™ ctDNA Assay for Molecular Profiling of Patients with Advanced NSCLC (2018) (0)
- Clinical characteristics and treatment outcomes of patients with pulmonary salivary gland-like tumors. (2016) (0)
- Platinum-based Adjuvant Chemotherapy for Resected Non-Small-Cell Lung Cancer: A New Standard of Care (2007) (0)
- Trends in Stage I Lung Cancer. (2022) (0)
- Phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer (NSCLC): Updated results of an ongoing study. (2004) (0)
- Genome-Wide Epigenomic Profiling of Primary Non-Small Cell Lung Cancer Reveals Specific and Recurrent DNA Methylation Alterations in Smoker Versus Never-Smoker Patients (2022) (0)
- Vascular endothelial growth factor trap in non-small cell lung cancer. Discussion (2007) (0)
- Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer (2018) (0)
- Association of Sleep Behaviors with Risk of Esophageal Cancer (2022) (0)
- P3-087: Phase II trial of sequenced bevacizumab and erlotinib with bevacizumab and chemotherapy for 1st line stage IIIB or IV Non-small cell lung cancer (NSCLC) (2007) (0)
- Outcomes in 708 resected stage I non-small cell lung cancer (NSCLC) subjects and a prognostic index for relapse (2005) (0)
- Bevacizumab of No Benefit to Older Patients with Lung Cancer (2012) (0)
- Abstract 1452: Analyses of whole exome sequencing (WES) data of hereditary lung cancer families identify germline copy number variations (CNVs) in multiple genes (2022) (0)
- Crizotinib induces Par-4 secretion from normal cells and GRP78 expression on the cancer cell surface for selective tumor growth inhibition. (2023) (0)
- Patterns of Care and Survival for Early Versus Delayed Radiation Therapy (RT) in Limited-Stage Small Cell Lung Cancer (LS-SCLC): A Review of the National Cancer Data Base (2016) (0)
- Next-Generation Sequencing for Lung Cancer in Clinical Practice (2017) (0)
- ED01.03 Insights from TCGA (2017) (0)
- MO4-1 Management of infusion-related reactions in patients receiving amivantamab in the CHRYSALIS study (2022) (0)
- P50.04 Amivantamab in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) (2021) (0)
- Abstract 6569: ClinGen Somatic and CIViC collaborate to comprehensively evaluate somatic variants in cancer (2023) (0)
- A pan-cancer PDX histology image repository with genomic and pathological annotations for deep learning analysis (2022) (0)
- Pulmonary neuroendocrine carcinomas: A population-based survey (2008) (0)
- Predicting Survival in Resected Lung Cancer (2012) (0)
- Small Cell Lung CancerPractice Guidelines in Oncology (2011) (0)
- Identification of community-consensus clinically relevant variants and development of single molecule molecular inversion probes using the CIViC database (2018) (0)
- A phase II and pharmacogenomic study of Irinotecan and carboplatin in advanced non-small cell lung cancer (NSCLC) (2005) (0)
- Characteristics of non-small cell lung cancer in patients under 40: a National Cancer Database (NCDB) Analysis 1998-2004: P1-036 (2007) (0)
- Takeaways from the World Conference on Lung Cancer (2014) (0)
- Progress in the treatment of metastatic non-small-cell lung cancer: slow but steady! (2009) (0)
- Reply to G. Bi et al. (2022) (0)
- Competing mortality (CM) risk in patients with resected stage I and II non-small cell lung cancer (NSCLC): A Surveillance, Epidemiology, and End Results (SEER) analysis. (2013) (0)
- MA 13.02 Comprehensive Genetic Analysis Related to PD-L1 Expression in Early-stage Lung Squamous Cell Carcinoma (2017) (0)
- Key Lung Cancer Takeaways from ASCO 2012 (2012) (0)
- Consolidation Chemotherapy Following Weekly Carboplatin-Paclitaxel Based Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer Is Associated With Improved Overall and Disease-Free Survival (2016) (0)
- A roundup of articles published in recent months. (2012) (0)
- P-617 Evaluating the impact of neoadjuvant chemotherapy and surgeryon quality of life (QL) in patients with early stage NSCLC: A prospective analysis of the GINEST project (2005) (0)
- Quality of Life in Patients with Advanced NSCLC Treated in Second-or Third-Line with Nab-Paclitaxel plus Durvalumab: ABOUND. 2L+ (2018) (0)
- IsThere a Role for Cetuximab in Non ^ Small Cell Lung Cancer? (2007) (0)
- Key Lung Cancer Takeaways from ASCO 2013 (2013) (0)
- Abstract CT191: Interim results from CLASSICAL-Lung, phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC (2020) (0)
- Nab-Paclitaxel plus Durvalumab as Second- or Third-Line Treatment of Advanced NSCLC: Results from ABOUND.2L+ (2017) (0)
- Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer. (2020) (0)
- Selumetinib for KRAS-Mutant Lung Cancer (2013) (0)
- Prognostic significance of tumor size in patients with stage III non-small cell lung cancer: A SEER database survey. (2009) (0)
- Abstract 5895: Whole-genome characterization of lung adenocarcinomas lacking alterations in RTK/RAS/RAF/MAPK pathway (2020) (0)
- P49.03 Chemoradiation with Cisplatin-Etoposide versus Carboplatin-Etoposide in Limited-Stage Small Cell Lung Cancer (2021) (0)
- A Phase I Study of Apolizumab, an Anti-HLA-DR ß-chain Monoclonal Antibody, in Patients With Solid Tumor Malignancies (2022) (0)
- 6549 POSTER Treatment of recurrent or progressive brain metastases with patupilone in patients with non-small cell lung cancer (NSCLC): results of a multicenter, open-label phase II study (2007) (0)
- A survey on insomnia in patients with non-small cell lung cancer (NSCLC). (2010) (0)
- Acknowledgment of Reviewers 2021. (2021) (0)
- Abstract 4682: Sunitinib (SU) in advanced NSCLC: Correlation of circulating biomarkers with clinical outcome (2010) (0)
- Lung cancer-related brain metastases: Further considerations (2008) (0)
- Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer (2023) (0)
- MA 03.01 Nab-Paclitaxel ± CC-486 as Second-Line Treatment of Advanced NSCLC: Results from the ABOUND.2L+ Study (2017) (0)
- A phase 1/2 study of VS-6766 (RAF/MEK clamp) in combination with sotorasib (G12C inhibitor) in patients with KRAS G12C mutant non–small cell lung cancer (NSCLC) (RAMP 203). (2022) (0)
- P1.05-047 Early Mortality in Patients with Non-Small Cell Lung Cancer Undergoing Adjuvant Chemotherapy: Topic: Neoadjuvant and Adjuvant Chemotherapy (2017) (0)
- Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment (2022) (0)
- Abstract 1202: A repository of PDX histology images for exploring spatial heterogeneity and cancer dynamics (2022) (0)
- Results from intermittent and continuous dosing schedules with sunitinib (SU) in previously treated, advanced non–small-cell lung cancer (NSCLC) (2008) (0)
- STATE OF THE ART AND SCIENCE Cancer Gene Sequencing: Ethical Challenges and Promises (2012) (0)
- Demystifying the Role of Tumor Mutational Burden for Immunotherapy Selection-Reply. (2020) (0)
- A phase I study of temsirolimus plus erlotinib in patients with refractory solid tumors. (2015) (0)
- Cause of death among patients with non-small cell lung cancer treated with postoperative radiation therapy (PORT). (2021) (0)
- P1.01-93 Quality of Life in Patients with Advanced NSCLC Treated in Second- or Third-Line with Nab-Paclitaxel + Durvalumab: ABOUND.2L+ (2018) (0)
- Practical Approach to the Treatment of Locally Advanced NSCLC: Controversies in Systemic Therapy (2008) (0)
- P2.01-040 Pemetrexed plus Platinum Chemotherapy with or Without Immunotherapy in Non-Squamous NSCLC: Descriptive Safety Analysis (2017) (0)
- The Paradox of the Efficacy of Local Treatment for Small-Cell Lung Cancer (2007) (0)
- Untangling the evolutionary roots of lung cancer (2019) (0)
- 100 Questions and Answers About Lung Cancer by Karen Parles and Joan H. Schiller (2008) (0)
- Tarlatamab, a first-in-class DLL3-targeted bispecific T cell engager, in recurrent small-cell lung cancer: an open-label, phase 1 study. (2023) (0)
- DeVita, Hellman, and Rosenberg's cancer (2013) (0)
- 2132: Survival of Patients With Esophageal Cancer Involving Gastric or Celiac Nodes (2006) (0)
- Role of the total mutation burden (TMB) and tumor-infiltrating lymphocytes (TILs) on the development of second primary cancer after complete resection of non-small cell lung cancer (NSCLC). (2020) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Ramaswamy Govindan?
Ramaswamy Govindan is affiliated with the following schools:
